Hope Biosciences Research Foundation clinical trials
Also known as HBRF, HBSCRF.
The registry lists 26 studies whose lead sponsor is Hope Biosciences Research Foundation. 1 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Our grouping of 1 registry name, not the registry’s. See them and correct one ↓
- 26studies on the registry
- 1open to participants now
- 1reach primary completion within a year
Get an email when these change. Save the Hope Biosciences Research Foundation studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Pipeline: 2 programmes
Each counted once: 2 with a study Hope Biosciences Research Foundation leads registered in the last two years.
- Phase 2
The 2 programmes — sign in to see the list, free: with every programme, filter by condition or phase and sort by first study or next readout.
“Registry” is the highest phase of Hope Biosciences Research Foundation’s own registered studies; Hope Biosciences Research Foundation’s own pipeline document is not read yet. “Next readout” is the earliest primary completion date still ahead among its live studies, as the registry states it (most are estimates). Programmes are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.
Coming up
1 of Hope Biosciences Research Foundation’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- 1JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- SSep
- OOct
- NNov
The study
- Jan 2027"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"NCT06800404
Add it to your calendar (.ics) → With an account.
All 26 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 320
- 21
- 22
- 23
- 24
- 25
- 226
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Hope Biosciences Research Foundation.
- Hope Biosciences Research Foundation26 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 26 of 26.
- HB-adMSCs for the Treatment of Crohn's DiseaseRecruitingNCT07077746Phase 2
- "An Intermediate Size Patient Population Expanded Access Protocol to Evaluate the Safety and Efficacy of Allogeneic HB-adMSCs (Hope Biosciences - Adipose Derived Mesenchymal Stem Cells) for the Treatment of Multiple System Atrophy."AvailableNCT07238062
- Intermediate Size Patient Population Expanded Access Protocol to Evaluate HB-adMSCs for the Treatment of Patients With Traumatic or Nontraumatic Brain InjuryNo longer availableNCT07164482
- Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)CompletedNCT04995081Phase 2
- Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)CompletedNCT04928287Phase 2
- HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic ArthritisWithdrawnNCT06623240Phase 2
- "HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"Active, not recruitingNCT06800404Phase 2
- Intermediate Size Expanded Access Protocol Using Autologous HB-adMSCs for the Treatment of Parkinson's DiseaseNo longer availableNCT06056427
- Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Spinal Cord InjuryNo longer availableNCT04064957
- Intermediate Size Expanded Access Protocol for the Treatment of Post-COVID-19 SyndromeNo longer availableNCT04798066
- An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)No longer availableNCT04825626
- Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral PalsyNo longer availableNCT04029896
- "Individual Patient Expanded Access IND to Treat Primary Lateral Sclerosis"No longer availableNCT04825613
- Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)No longer availableNCT04907175
- Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral SclerosisNo longer availableNCT04514952
- Individual Patient Expanded Access IND for the Treatment of StrokeNo longer availableNCT04907188
- Individual Patient Expanded Access IND of HB-adMSCs for Chronic Musculoskeletal Pain.No longer availableNCT04711811
- Individual Patient Expanded Access IND to Treat PolyneuropathyNo longer availableNCT04064983
- Individual Patient Expanded Access IND of Autologous HB-adMSCS for the Treatment of Bilateral Knee Pain.No longer availableNCT04604288
- HBCMD01- Expanded Access for the Treatment of Congenital Muscular Dystrophy.No longer availableNCT05154851
- Intermediate Size Patient Population Expanded Access IND for the Treatment of Patients With Parkinson's Disease.No longer availableNCT04772378
- A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19CompletedNCT04349631Phase 2
- Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple SclerosisCompletedNCT05116540Phase 2
- Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19TerminatedNCT04362189Phase 2
- A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.CompletedNCT04348435Phase 2
- Randomized Double-Blind Phase 2 Study of Allogeneic HB-adMSCs for the Treatment of Chronic Post-COVID-19 SyndromeCompletedNCT05126563Phase 2